Vermox 100 mg tabl. – Belgian medicines register entry (Geneesmiddelendatabank, FAGG/AFMPS) (2026)

Other · Federal Agency for Medicines and Health Products (FAGG/AFMPS), Belgium · November 19, 2026

Federal Agency for Medicines, 2026-11-19: The Belgian national medicines register records Vermox 100 mg tablets with a first marketing authorisation date of 1 March 1971 and Kenvue Belgium SA-NV as the current company. It is primary regulatory evidence that mebendazole was nationally authorised in Belgium in 1971, the same year as the first JAMA clinical paper.

Actief bestanddeel Mebendazol 100 mg Farmaceutische vorm Tablet Toedieningsweg Oraal gebruik Firma Kenvue Belgium SA-NV Vergunningstype Vergunning voor het in de handel brengen Datum eerste vergunning 1 March 1971

Federal Agency for Medicines, 2026-11-19: The Belgian national medicines register records Vermox 100 mg tablets with a first marketing authorisation date of 1 March 1971 and Kenvue Belgium SA-NV as the current company. It is primary regulatory evidence that mebendazole was nationally authorised in Belgium in 1971, the same year as the first JAMA clinical paper. Foreign-language record (Dutch), quoted in the original. Translation of the quoted fields: 'Active substance Mebendazole 100 mg; Pharmaceutical form Tablet; Route of administration Oral use; Company Kenvue Belgium SA-NV; Authorisation type Marketing authorisation; Date of first authorisation 1 March 1971.' Also recorded on the page: authorisation number BE001057; ATC P02CA01 Mebendazole; legal basis 'FULL AUTHORISATION – Article 2.8, first paragraph of the Royal Decree of 3/7/1969'; one pack shown as 'Niet gecommercialiseerd' (not marketed/cn: 'not commercialised') and another as available. Record-field transcription, access date 2026-11-19 (page undated). This entry is also cited in the EMA list at MBA-40 (BE001057).